This happens once in a lifetime of research; for a scientist, its like being on the front page of Times Magazine.
The paper is called: GC protein-derived macrophage-activating factor decreases a-N-acetylgalactosaminidase levels in advanced cancer patients.
Or to translate: GcMAF decreases nagalase in advanced cancer patients.
It follows the excellent improvements in 20 cancer patients with two of our GcMAF doctors.
You can see the front page at: https://www.landesbioscience.com/journals/oncoimmunology/